As soon as 48 hours,* NEMLUVIO relieves itch fast, with skin healing that lasts in AD^1,2

Name: Nemluvio HCP
Creator: Nemluvio

Fast Itch Relief¹

See how NEMLUVIO^® provided fast and lasting itch relief¹

VIEW THE DATA

Lasting Skin Healing²

Discover how NEMLUVIO helped most patients with AD achieve lasting skin clearance²

SEE THE DIFFERENCE

Favorable Safety Profile³

NEMLUVIO was well tolerated, has no boxed warning, and requires no preliminary lab evaluations or ongoing lab monitoring³

REVIEW SAFETY PROFILE

The ARCADIA Trials Reflect Topical Use in AD Clinical Practice^2-6

To capture the reality of many with AD, the ARCADIA trials only included those who failed with topical treatment^2-6

REVIEW TRIAL

Experiencing a new reality

See how Whitney relieved her unrelenting itch and achieved lasting skin healing with NEMLUVIO

Transcript

At that moment, it was the worst that my skin's ever been. I was itchy. I felt this like constant flush, like I was on fire every day. My skin was always red, inflamed, flaky. It was painful.

There were days where my hands were cracked so much that I couldn't even do my job, and others would have to kind of pick up the slack. So that way, you know, things still got done.

I couldn't go out and hang out with my kids to go do things because my skin hurts so bad. I just wanted to be still. Even when you're still, it still hurts.

There's lots of different older treatments, like bleach baths and wet wrapping, light therapy, allergy testing with that includes, you know, getting shots or doing drops and that just took so much time out of my life.

Since starting the NEMLUVIO, I'm not itchy. I would definitely say that my disease was managed with NEMLUVIO at 4 weeks, I've noticed significant improvement in my skin areas of like around my eyes and my hands that were just terrible before and now they're like feeling refreshed.

The skin is healed, and it's not painful. It's important to know that there's other things out there, that there's people that want to help you.

Sign up now for more information about NEMLUVIO for AD

SIGN UP

PP-NRS response defined as a ≥4-point improvement from baseline. Data from Phase 3 clinical study (ARCADIA 1) post hoc descriptive analysis of daily PP-NRS improvement; consistent results seen in ARCADIA 2. Significant improvement was achieved at 48 hours (9% with NEMLUVIO + TCS/TCI vs 3% with placebo + TCS/TCI, P≤0.001).^1,2

AD=atopic dermatitis; PP-NRS=Peak Pruritus Numerical Rating Scale; TCSI=topical calcineurin inhibitor; TCS=topical corticosteroid.

References: 1. Galderma Laboratories, L.P.; data on file. 2. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SIR.118163 [ARCADIA LTE]; October 2023. 3. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 4. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SRE.118161 [ARCADIA 1]; September 2023. 5. Misery L, Brenaut E, Pierre O, et al. Chronic itch: emerging treatments following new research concepts. Br J Pharmacol. 2021;178(24):4775-4791. doi:10.1111/bph.15672 6. Orfali RL, Aoki V. Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis. Pharmaceutics. 2023;15(2):577. doi:10.3390/pharmaceutics15020577

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO^® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia.
Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular.

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.

As soon as 48 hours,* NEMLUVIO relieves itch fast, with skin healing that lasts in AD1,2

The ARCADIA Trials Reflect Topical Use in AD Clinical Practice2-6

Experiencing a new reality

Sign up now for more information about NEMLUVIO for AD

As soon as 48 hours,* NEMLUVIO relieves itch fast, with skin healing that lasts in AD^1,2

The ARCADIA Trials Reflect Topical Use in AD Clinical Practice^2-6